الفهرس 
Contents
Prognostic factorsOnly 14 pages are availabe for public view
 |  | from | 97 |  |  |
| | | from | 97 | | |
Abstract
Introduction: Acute myeloid leukemia (AML) is the commonest type of acute leukemia in adults that resulting from a clonal proliferation of bone marrow precursor cells with disruption of hemostasis. Patients initially respond to induction therapy but the majority of patients suffer relapse with very poor subsequent prognosis The aim of work: was to comparing the two widely used salvage regimens in treatment of relapsed/refractory AML (cytarabine, novantron, Colony stimulating factor) versus (cytarabine, fludarabine, Colony stimulating factor) protocols.Research Plan:. This prospective randomized study included 90 patient diagnosed as relapsed/refractory AML, who selected from Oncology center in Mansoura, Egypt from 2014 to 2017. Patients who previously treated by first line chemotherapy received salvage therapy either HAM of FLAG protocol, after that the outcome in term of efficacy, side effects and overall survival was assessed. Results: Conclusion:. 90 were included, 18 female patients (38.35%), 29 male patients (61.7%) received HAM protocol (total number was 47 patients) versus 13 female patients (30.2%), 30 male patients (69.8%) received FLAG protocol. Eight patients (72.7%) not achieved CR ,3 patients (27.3%) achieved CR after 2nd line salvage therapy in HAM group versus 3 patients (27.3%) not achieved CR,1 patient (16.7%) achieved CR after 2nd line salvage therapy in FLAG group (P " ~ " 0.6) Conclusion: protocol FLAG ha better OS compared with protocol HAM with accepted toxicity profile, further studies may be recommended on larger sample size to emphasize correctly their usage.